Navigation Links
ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
Date:9/24/2007

OXFORD, England, September 24 /PRNewswire/ -- ProImmune Ltd., a leading provider of quality research reagents for monitoring the immune system and services for antigen discovery, has announced the launch of its new MHC-peptide binding assay for Class II HLA alleles, adding to the series of discovery services for Class I HLA already available from the Company.

The Class II REVEAL(TM) binding assay for HLA alleles DR1-4, is a powerful cell-free in vitro assay that can rapidly predict T-cell antigens in any protein sequence. It is widely applicable across many disease areas such as cancer, infectious diseases, autoimmunity and in transplantation, and is ideally suited to therapeutic programmes with time pressures, such as the development of vaccines for emerging diseases.

Unlike traditional methods for discovering T-cell antigens, such as functional cellular assays, the Class II REVEAL(TM) assay does not use patient samples, and uniquely determines the HLA restriction of each antigen in a single step. Class II REVEAL(TM) therefore offers a significant timesaving advantage, and reduces the overall cost and risk of discovery projects.

The launch of Class II REVEAL(TM) follows ProImmune's recent extension of its range of MHC Class II Ultimer(TM) staining reagents with alleles DR2 and DR3 to cover HLA DR1 to 4. Class II Ultimers(TM) can be used to validate antigens discovered with REVEAL(TM), and in monitoring and phenotyping of targeted immune responses.

Dr. Nikolai Schwabe, CEO of ProImmune, said "Class II REVEAL(TM) helps to overcome a significant barrier in understanding key helper T-cell immune responses in detail, and to harness such responses in the design of highly targeted therapies across a very wide range of diseases".

ProImmune Ltd is a private biotechnology company based in Oxford, UK, that specializes in providing antigen discovery services and research reagents for monitoring the immune system. ProImmune has a wide range of customers from pharmaceutical and biotechnology companies, to clinical and academic research institutes throughout the world. The Company, founded in November 1999, has secured R&D funding from several DTI Smart, EUREKA and EU Framework VI project grants and has been profitable since its inception. ProImmune owns a portfolio of international patents and patent applications protecting its core products and technologies. The Company also has offices in the USA. http://www.proimmune.com

Media enquiries:

Gemma Price

Northbank Communications

Tel: +44-(0)-20-7268-3002

Email: g.price@northbankcommunications.com


'/>"/>
SOURCE ProImmune Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. TeraMedica launches information manager
7. GE Healthcare launches hybrid electronic record
8. Cedara launches new version of DICOM toolkit
9. Merge launches Spanish version of imaging tool
10. Doyle launches 2025 alternative energy plan
11. Jellyfish launches comparative shopping website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016 This report analyzes the worldwide ... Acid Based (Humic, Amino, & Fulvic), Extract Based, and Others. ... Crop Types: Ornamental & Turf, Row Crops, and Others. The ... Canada , Japan , ... Latin America , and Rest of World. Annual estimates ...
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... finalists in the World Technology Awards. uBiome is one of just six company ... all categories. , In addition to uBiome, companies nominated as finalists in this ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
Breaking Biology News(10 mins):